Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 ...
2024-02-13 08:25:14 ET Summary Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ability to execute business development activities a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 ...
BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover t...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 ...
Preliminary results from HELIOS anticipated in the second half of 2024 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has completed enrollment of its Phase 2 HELIOS trial of AMX0035 (sodium phenylbutyrate [PB] a...
2024-01-21 13:16:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life. In turn, the firms that can produce therapeutics that address huma...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Amylyx To Contact Him Directly To Discuss Their Options If you suffered significant losses in Amylyx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi ...
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ). The investigation concerns whether Amylyx and/or certain of its o...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...